Compare TG Therapeutics Inc (TGTX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Under Armour Inc Class A — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: TG Therapeutics Inc is far larger — about 3.9× Under Armour Inc Class A's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Under Armour Inc Class A for 18 Days on average.
| TGTX | UA | |
|---|---|---|
Market Cap | $8.16B | $2.07B |
Volume | 1,735,121 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $7.88 |
52-Week Low | $26.94 | $3.96 |
Typical Hold Time | 16 Days | 18 Days |
Enterprise Value | $8.37B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Under Armour (UA) trades at $4.78, up 1.7% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly results with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst consensus shows 40% buy ratings but sentiment remains cautious due to ongoing revenue challenges and negative cash flow trends.
The outlook remains challenging with declining revenue and persistent losses, though the stock's low P/S ratio of 0.41 offers valuation support. Key risks include weak North American demand and competitive pressures, while potential catalysts require successful execution of turnaround strategies to restore profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
